Mark Stencik

Mark Stencik
Executive Director, Business Development & Licensing

Merck Boston Innovation Hub

Mark has nearly twenty years of Biotech/Pharma experience in business development and licensing and raising capital. Mark currently leads transactions at the Merck Boston Innovation Hub, which is a fully functional business development and licensing group focused on early-stage therapeutics (pre proof-of-concept in clinic) as well as accessing innovative research and technologies through collaboration, licensing, or mergers and acquisitions in the academic, pharma and biotech communities.  Mark has led the negotiation and completion of numerous complex transactions, including Merck’s acquisitions of Pandion and Tilos Therapeutics as well as licensing deals with Amathus, Foghorn, Skyhawk, Dragonfly, Cue, and Moderna, among others.  Prior to Merck, Mark spent over five years at Vertex Pharmaceuticals in Business Development and Strategic Operations roles. Prior to that he spent time at Amgen in various roles including Treasury and Business Development & Strategy. Mark holds a B.S. in Accounting from the Pennsylvania State University and an MBA from New York University.